NCT03081702View on ClinicalTrials.gov

A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 25, 2017

Primary Completion Date

August 27, 2019

Study Completion Date

August 27, 2019

Conditions
Platinum-resistant Epithelial Ovarian Cancer
Interventions
DRUG

Hydroxychloroquine

Hydroxychloroquine is approved/used for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, as well as suppressive treatment and treatment of acute attacks of malaria.

DRUG

Itraconazole

Itraconazole is approved and used for the treatment of certain systemic fungal infections.

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT03081702 - A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter